Pemoline hepatotoxicity and postmarketing surveillance

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 40, Issue 6, 2001, Pages 622-629

  Safer, Daniel J ^a,c   Zito, Julie Magno ^b   Gardner, James F ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c NONE   (United States)

Author keywords

Adverse drug reaction; Attention deficit hyperactivity disorder; Pemoline; Postmarketing surveillance

Indexed keywords

PEMOLINE;

ATTENTION DEFICIT DISORDER; DEATH; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; JAUNDICE; LIVER TOXICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0035018869     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200106000-00006     Document Type: Article

References (51)

1. Adcock KG, MacElroy DE, Wolford ET, Farrington EA (1998), Pemoline therapy resulting in liver transplantation. Ann Pharmacother 32:422-425
2. Anonymous (2000), Anti-heartburn drug [Propulsid] linked to 80 deaths is pulled off market. Baltimore Sun March 24, p 2A
3. Baum C, Kweder SL, Anello C (1994), The spontaneous reporting system in the United States. In: Pharmacoepidemiology, 2nd ed, Strom BL, ed. New York: Wiley, pp 125-137
4. Berkovitch M, Pope E, Phillips J, Koren G (1995), Pemoline-associated fulminant liver failure. Clin Pharmacol Ther 57:696-698
5. Brewer T, Colditz GA (1999), Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 281:824-829
6. Carrey NJ, Wiggins DM, Milin RP (1996), Pharmacological treatment of psychiatric disorders in children and adolescents. Drugs 51:750-759
7. Corr PB (2000), Rezulin to be withdrawn from the market. Drug warning letter to physicians, Warner-Lambert Company, Ann Arbor, MI, March 22
8. David T, Vale A (1981), Pemoline poisoning. Arch Toxicol 48:205-207
9. Devictor D, Desplanques L, Debray D, Ozier Y (1992), Emergency liver transplantation for fulminant liver failure in infants and children. Hepatology 16:1156-1162
10. Elia J (1993), Drug treatment for hyperactive children. Drug 46:863-871
11. Elitsur Y (1990), Pemoline (Cylert)-induced hepatotoxicity (letter). J Pediatr Gastrenterol Nutr 11:143-144
12. Fletcher AP (1999), UK primary care databases lead the way. Adverse Drug React Toxicol Rev 18:57-60
13. Gilbert JG, Donnelly KJ, Zimmer LE, Kubis JF (1973), Effect of magnesium pemoline and methylphenidate on memory improvement and mood in normal aging subjects. Int J Aging Hum Dev 4:35-51
14. Greenhill LL (1995), Attention-deficit hyperactivity disorder. Child Adolesc Pychiatr Clin N Am 4:123-168
15. Greenhill LL (2000), Evidence-based stimulant treatments for ADHD. Presented at the 123rd meeting of the Am Psychiatric Association, Chicago, May 18
16. Health Canada (1999), Liver complication results in withdrawal of attention deficit hyperactivity disorder drug, Cylert; September; http://www.hc-sc.gc.calenglish/archives/warnings/99.13e.htm
17. Hochman JA, Woodward SA, Cohen MB (1998), Exacerbation of autoimmune hepatitis: another hepatotoxic effect of pemoline therapy. Pediatrics 101:106-108
18. IMS America Ltd (2000), Plymouth Meeting, PA
19. Jaffe SL (1989), Pemoline and liver function. J Am Acad Child Adolesc Pychiatry 28:457-458
20. Juergens JP (1990), Controversies in adverse drug reaction reporting. Am J Hosp Pharm 47:76-77
21. Kessler DA (1993), Introducing MedWatch. JAMA 269:2765-2768
22. Lee WM (1993), Acute liver failure. N Engl J Med 329-1862-1872
23. MacKay FJ (1998), Post-marketing studies: the work of the Drug Safety Research Unit. Drug Saf 19:343-353
24. Marotta PJ, Roberts EA (1998), Pemoline hepatotoxicity in children. J Pediatr 132:894-897
25. McCurry L, Cronquist S (1997), Pemoline and hepatotoxicity. Am J Psychiatry 154:713-714
26. McNeil JR (1979), Accidental ingestion of pemoline. Clin Pediatr (Phila) 18:761-762
27. Medicines Control Agency (1997), Volital (pemoline) has been withdrawn. Curr Probl Pharmacovigilance 23:10, September
28. Med Watch (2000), http://www.fda.gov/cder/adr
29. Moore TJ, Psary BM, Furberg CD (1998), Time to act on drug safety. JAMA 279:1571-1573
30. Moride Y, Haramburu G, Requejo AA, Begaud B (1997), Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 43:177-181
31. Nehra A, Mullick R, Ishak KG, Zimmerman HJ (1990), Pemoline-associated hepatic injury. Gastroenterology 99:1517-1519
32. Page JG, Bernstein JE, Janicki RS, Michelli FA (1974), A multi-clinic trial of pemoline in childhood hyperkinesis. In: Clinical Use of Stimulant Drugs in Children, Conners CK, ed. Amsterdam: Excerpta Medica, pp 98-124
33. Patterson JF (1984), Hepatitis associated with pemoline. South Med J 77:938
34. Pizzuti D (1996), Black box warning letter, Cylert. Abbott Laboratories, Abbott Park, IL, December
35. Pizzuti D (1999), Revised black box warning, Cylert. Abbott Laboratories, Abbott Park, IL, June
36. Pratt DS, Dubois RS (1990), Hepatotoxicity due to pemoline (Cylert): a report of two cases. J Pediatr Gastroenterol Nutr 10:239-241
37. Rosh JR, Dellert SF, Narkewicz M, Birnbaum A, Whitington G (1998), Four cases of severe hepatotoxicity associated with pemoline. Pediatrics 101:921-923
38. Safer DJ, Zito JM, Gardner JF (2000), Trends in pemoline treatment and its adverse drug reactions in youths. Presented at the 40th annual meeting of NCDEU (abstract, poster no. 64). Boca Raton, FL, June 1
39. Scott HD, Rosenbaum SE, Walters WJ (1987), Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 70:311-316
40. Shah RR (1999), Drug-induced hepatotoxicity. Adverse Drug React Toxicol Rev 18:181-233
41. Shatin D, Gardner JS (1999), Time for action on drug safety. JAMA 281:319-320
42. Sterling MJ, Kane M, Grace ND (1996), Pemoline-induced autoimmune hepatitis. Am J Gastroenterol 91:2233-2234
43. Sylvester C (1993), Psychopharmacology of disorders of children. Psychiatr Clin North Am 16:779-791
44. Tolman KG, Freston JW, Berenson MM, Sannella JJ (1973), Hepatotoxicity due to pemoline. Digestion 9:532-539
45. US FDA Center for Drug Evaluation and Research (1999), ADRS Division of Pharmacovigilance and Epidemiology, Rockville, MD 20857; http://www.fda.gov/cderladrlindex.htm. May 18
46. US General Accounting Office (1990), FDA Drug Review: Postapproval Risks 1976-1985. Washington, DC, GAO/PEMD 90-15. April 26
47. Yenning GR (1983), Identification of adverse reactions to new drugs, II: how were 18 important adverse drug reactions discovered with what delays? BMJ 286:289-292
48. Waslick B, Greenhill L (1997), Attention-deficit hyperactivity disorder. In: Textbook of Child and Adolescent Psychiatry, 2nd ed, Wiener JM, ed. Washington, DC: American Psychiatric Press, pp 389-410
49. Wilens TE, Biederman J (1992), The stimulants. Pychiatr Clin North Am 15:191-222
50. Wiholm BE, Olsson S, Moore N, Wood S (1994), Spontaneous reporting systems outside the United States. In: Pharmacoepidemiology, 2nd ed, Strom BL, ed. New York: Wiley, pp 143-155
51. Wood AJ, Stein CM, Woosley R (1998), Making medicines safer: the need for an independent drug safety board. N Engl J Med 339:1851-1854